ID: ALA113534

Max Phase: Preclinical

Molecular Formula: C26H25ClN8O

Molecular Weight: 500.99

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(NC(=O)c2ccc(/N=N/N(C)CCCl)cc2)cc1Nc1nccc(-c2cccnc2)n1

Standard InChI:  InChI=1S/C26H25ClN8O/c1-18-5-8-22(30-25(36)19-6-9-21(10-7-19)33-34-35(2)15-12-27)16-24(18)32-26-29-14-11-23(31-26)20-4-3-13-28-17-20/h3-11,13-14,16-17H,12,15H2,1-2H3,(H,30,36)(H,29,31,32)/b34-33+

Standard InChI Key:  AUHKMKATZQLPOZ-JEIPZWNWSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 500.99

Molecular Weight (Monoisotopic): 500.1840

AlogP: 6.01

#Rotatable Bonds: 9

Polar Surface Area: 107.76

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 12.69

CX Basic pKa: 4.26

CX LogP: 5.65

CX LogD: 5.65

Aromatic Rings: 4

Heavy Atoms: 36

QED Weighted: 0.17

Np Likeness Score: -1.62

References

1. Rachid Z, Katsoulas A, Brahimi F, Jean-Claude BJ..  (2003)  Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase.,  13  (19): [PMID:12951113] [10.1016/s0960-894x(03)00553-5]

2. Cui J, Fu R, Zhou LH, Chen SP, Li GW, Qian SX, Liu S..  (2013)  BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives.,  23  (8): [PMID:23473682] [10.1016/j.bmcl.2013.01.113]

Source

Source(1):

• Scientific Literature